$XENE News

JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $82

Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $80

RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $82

Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $78

Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript

Xenon Pharmaceuticals (NASDAQ:XENE) Reports Mixed Q1 Results as Azetukalner Nears FDA Submission

XENON PHARMACEUTICALS INC (NASDAQ:XENE) Breakout Setup Combines 9/10 Technical Strength with 9/10 Consolidation Quality

Xenon Pharmaceuticals Inc (XENE) Looking At a $2 Billion Opportunity Here

Xenon's Phase 3 Supports A 'Buy' Despite Its Premium

Reported Sunday, Xenon Presents Phase 3 X-TOLE2 Data Showing Azetukalner Delivers 53.2% Reduction In Monthly Seizure Frequency Versus 10.4% For Placebo In Focal Onset Seizures At AAN 2026

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

Xenon to Present at Upcoming Investor Conferences

Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting

Xenon To Highlight Topline Phase 3 X-TOLE2 Study Results For Azetukalner In FOS, And Poster Presentation Of Long-Term 48-Month Azetukalner Data From X-TOLE Open Label Extension Study At 2026 AAN Annual Meeting

Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know

Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why

Xenon Pharmaceuticals (XENE) Is Down 6.7% After $650 Million Follow-On Offering And Phase 3 Epilepsy Win

Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $63

Xenon Pharmaceuticals (XENE) Climbs 31.7% as Epilepsy Treatment Moves Forward